Skip to main content
Fig. 1 | Molecular Brain

Fig. 1

From: Inhibition of DREAM-ATF6 interaction delays onset of cognition deficit in a mouse model of Huntington’s disease

Fig. 1

Repaglinide delays the onset of cognitive impairment in R6/1 mice. Memory was assessed in 16- (a) and 20-weeks (b) wt or R6/1 old mice using the novel object recognition test. Mice received repaglinide (RP) or vehicle (DMSO) in drinking water from shortly after weaning. The discrimination index (D.I.) reflects the ability to recognize novelty 4 or 24 h after first exposure to the object. The number of mice included in the novel object recognition test: wt-DMSO (26–31), wt-RP (14–21), R6/1-DMSO (18–37), R6/1-RP (12–20). c Circulating glucose levels in 20-week-old mice of the indicated genotype and treatment. After overnight fasting, mice had access to food pellets for 1 h before testing. The number of mice used for glucose determination: wt-DMSO (10), wt-RP (15), R6/1-DMSO (10), R6/1-RP (20). d Body weight of 20-week-old male mice of the indicated genotype and treatment. The number of mice used for body weight determination: wt-DMSO (9), wt-RP (6), R6/1-DMSO (6), R6/1-RP (6). Data are shown as mean ± SEM. Non-parametric ANOVA, Kruskal-Wallis test (P values: a) 0.0014 and 0.006 for 4 and 24 h, respectively; b) 0.0003 and 0.0118 for 4 and 24 h, respectively; c) 0.0017; d) 0.0009) with Dunn’s multiple comparisons between selected groups was used, *** p <0.005, ** p <0.01, * p <0.05 vs wt-DMSO, # p <0.05, R6/1-RP vs R6/1-DMSO

Back to article page